Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias

Am J Hematol. 2018 Jul;93(7):E172-E175. doi: 10.1002/ajh.25122. Epub 2018 May 15.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anemia / complications
  • Anemia / therapy*
  • Blood Transfusion
  • Child
  • Creatinine / blood
  • Deferasirox / adverse effects*
  • Deferasirox / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Iron Chelating Agents / therapeutic use
  • Iron Overload
  • Kidney Diseases / chemically induced
  • Kidney Diseases / etiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Retrospective Studies
  • Young Adult
  • beta-Thalassemia / complications
  • beta-Thalassemia / therapy*

Substances

  • Iron Chelating Agents
  • Creatinine
  • Deferasirox